AMENDED AND RESTATED CHANGE-IN-CONTROL AGREEMENTChange-in-Control Agreement • March 3rd, 2004 • Invitrogen Corp • Biological products, (no disgnostic substances) • Delaware
This AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT (“the Agreement”) by and between INVITROGEN CORPORATION, a Delaware Corporation (the “Company”), and C. Eric Winzer (the “Executive”), dated as of the 16th day of October 2003.
INVITROGEN CORPORATION RESTRICTED STOCK AGREEMENTInvitrogen Corporation • March 3rd, 2004 • Invitrogen Corp • Biological products, (no disgnostic substances) • California
Invitrogen Corporation (the “Company”) has granted to Benjamin Bulkley (the “Participant”) an Award consisting of Shares subject to the terms and conditions set forth in this Restricted Stock Agreement (the “Agreement”). The Award has been granted pursuant to the Invitrogen Corporation 2002 Stock Incentive Plan (formerly the Molecular Probes, Inc. 2002 Stock Incentive Plan) (the “Plan”) and as an essential and material inducement to the Participant accepting employment with the Company. By signing this Agreement, the Participant: (a) represents that the Participant has read and is familiar with the terms and conditions of the Award, this Agreement and the Plan, (b) accepts the Award subject to all of the terms and conditions of this Agreement and the Plan, (c) agrees to accept as binding, conclusive and final all decisions or interpretations of the Board upon any questions arising under this Agreement, and (d) acknowledges receipt of a copy of this Agreement and the Plan.
AGREEMENT AND PLAN OF MERGER among INVITROGEN CORPORATION BASEBALL ACQUISITION CORPORATION and BIORELIANCE CORPORATION Dated as of December 24, 2003Agreement and Plan of Merger • March 3rd, 2004 • Invitrogen Corp • Biological products, (no disgnostic substances) • Delaware
AGREEMENT AND PLAN OF MERGER, dated as of December 24, 2003 (this “Agreement”), by and among INVITROGEN CORPORATION, a Delaware corporation (“Parent”), BASEBALL ACQUISITION CORPORATION, a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”), and BIORELIANCE CORPORATION, a Delaware corporation (the “Company”).
